AU2007224967A1 - Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover - Google Patents
Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover Download PDFInfo
- Publication number
- AU2007224967A1 AU2007224967A1 AU2007224967A AU2007224967A AU2007224967A1 AU 2007224967 A1 AU2007224967 A1 AU 2007224967A1 AU 2007224967 A AU2007224967 A AU 2007224967A AU 2007224967 A AU2007224967 A AU 2007224967A AU 2007224967 A1 AU2007224967 A1 AU 2007224967A1
- Authority
- AU
- Australia
- Prior art keywords
- smad2
- phospho
- markers
- mcl
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 226
- 210000002993 trophoblast Anatomy 0.000 title claims description 136
- 230000030833 cell death Effects 0.000 title claims description 86
- 230000007910 cell fusion Effects 0.000 title claims description 70
- 230000024245 cell differentiation Effects 0.000 title claims description 65
- 230000003822 cell turnover Effects 0.000 title claims description 63
- 230000004709 cell invasion Effects 0.000 title claims description 62
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000011282 treatment Methods 0.000 title description 27
- 230000014509 gene expression Effects 0.000 claims description 243
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 231
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 222
- -1 phospho-SMAD2 Proteins 0.000 claims description 221
- 102000040430 polynucleotide Human genes 0.000 claims description 217
- 108091033319 polynucleotide Proteins 0.000 claims description 217
- 239000002157 polynucleotide Substances 0.000 claims description 217
- 229920001184 polypeptide Polymers 0.000 claims description 217
- 239000000523 sample Substances 0.000 claims description 212
- 201000011461 pre-eclampsia Diseases 0.000 claims description 157
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 135
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims description 127
- 101700026522 SMAD7 Proteins 0.000 claims description 126
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 115
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 115
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 115
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 115
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 101
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 94
- 230000035935 pregnancy Effects 0.000 claims description 87
- 208000030941 fetal growth restriction Diseases 0.000 claims description 73
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 72
- 102000011727 Caspases Human genes 0.000 claims description 63
- 108010076667 Caspases Proteins 0.000 claims description 63
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 55
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 55
- 102000001708 Protein Isoforms Human genes 0.000 claims description 54
- 108010029485 Protein Isoforms Proteins 0.000 claims description 54
- 102100021696 Syncytin-1 Human genes 0.000 claims description 50
- 108010037253 syncytin Proteins 0.000 claims description 50
- 108020004999 messenger RNA Proteins 0.000 claims description 45
- 238000012360 testing method Methods 0.000 claims description 45
- 108010036395 Endoglin Proteins 0.000 claims description 42
- 102000012085 Endoglin Human genes 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 36
- 239000011230 binding agent Substances 0.000 claims description 35
- 230000033228 biological regulation Effects 0.000 claims description 34
- 230000003247 decreasing effect Effects 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- 238000002493 microarray Methods 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 102100039193 Cullin-2 Human genes 0.000 claims description 26
- 108700004934 NEDD8 Proteins 0.000 claims description 26
- 102100031911 NEDD8 Human genes 0.000 claims description 26
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 26
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 claims description 26
- 238000009396 hybridization Methods 0.000 claims description 26
- 101710094489 Cullin-2 Proteins 0.000 claims description 25
- 201000005608 severe pre-eclampsia Diseases 0.000 claims description 24
- 239000013615 primer Substances 0.000 claims description 23
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 claims description 22
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 21
- 102100031748 E3 ubiquitin-protein ligase SIAH2 Human genes 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 20
- 239000002299 complementary DNA Substances 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 238000012544 monitoring process Methods 0.000 claims description 16
- 238000003752 polymerase chain reaction Methods 0.000 claims description 16
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 102100021838 E3 ubiquitin-protein ligase SIAH1 Human genes 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 13
- 101150064015 FAS gene Proteins 0.000 claims description 13
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 13
- 239000002987 primer (paints) Substances 0.000 claims description 12
- 101150070607 Siah2 gene Proteins 0.000 claims description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 101710128187 E3 ubiquitin-protein ligase Siah1 Proteins 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000000090 biomarker Substances 0.000 claims description 8
- 230000007306 turnover Effects 0.000 claims description 8
- 239000003155 DNA primer Substances 0.000 claims description 6
- 101710128185 E3 ubiquitin-protein ligase Siah2 Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 239000013068 control sample Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims 31
- 102100037249 Egl nine homolog 1 Human genes 0.000 claims 10
- 101710111663 Egl nine homolog 1 Proteins 0.000 claims 10
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 claims 10
- 101710170720 Prolyl hydroxylase EGLN3 Proteins 0.000 claims 10
- 101150107958 NEDD8 gene Proteins 0.000 claims 4
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 claims 4
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 claims 4
- 101150024074 rub1 gene Proteins 0.000 claims 4
- 102000057208 Smad2 Human genes 0.000 description 105
- 230000001965 increasing effect Effects 0.000 description 91
- 239000003550 marker Substances 0.000 description 88
- 230000003169 placental effect Effects 0.000 description 80
- 206010021143 Hypoxia Diseases 0.000 description 70
- 210000001519 tissue Anatomy 0.000 description 67
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 62
- 239000001301 oxygen Substances 0.000 description 62
- 229910052760 oxygen Inorganic materials 0.000 description 62
- 230000007954 hypoxia Effects 0.000 description 58
- 102000004169 proteins and genes Human genes 0.000 description 51
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 37
- 102000006108 VHL Human genes 0.000 description 36
- 101150046474 Vhl gene Proteins 0.000 description 36
- 108090000397 Caspase 3 Proteins 0.000 description 33
- 102100029855 Caspase-3 Human genes 0.000 description 33
- 230000027455 binding Effects 0.000 description 33
- 210000005059 placental tissue Anatomy 0.000 description 33
- 238000006213 oxygenation reaction Methods 0.000 description 32
- 230000001575 pathological effect Effects 0.000 description 28
- 238000012384 transportation and delivery Methods 0.000 description 28
- 238000003119 immunoblot Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 230000001684 chronic effect Effects 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- 238000003776 cleavage reaction Methods 0.000 description 24
- 230000007017 scission Effects 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 238000010186 staining Methods 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000001105 regulatory effect Effects 0.000 description 22
- 230000001404 mediated effect Effects 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 17
- 230000000875 corresponding effect Effects 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 230000008774 maternal effect Effects 0.000 description 16
- 239000003531 protein hydrolysate Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 208000034423 Delivery Diseases 0.000 description 15
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 15
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 15
- 108010048418 alpha Subunit Hypoxia-Inducible Factor 1 Proteins 0.000 description 15
- 102000009120 alpha Subunit Hypoxia-Inducible Factor 1 Human genes 0.000 description 15
- 230000006907 apoptotic process Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 108010031256 phosducin Proteins 0.000 description 15
- 210000002826 placenta Anatomy 0.000 description 15
- 238000002405 diagnostic procedure Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 230000028742 placenta development Effects 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 102000004091 Caspase-8 Human genes 0.000 description 13
- 108090000538 Caspase-8 Proteins 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000003491 array Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 230000036266 weeks of gestation Effects 0.000 description 11
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000001594 aberrant effect Effects 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 230000001640 apoptogenic effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000000861 pro-apoptotic effect Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 208000007530 Essential hypertension Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108091007354 SIAHs Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 6
- 102000053642 Catalytic RNA Human genes 0.000 description 6
- 208000006332 Choriocarcinoma Diseases 0.000 description 6
- 208000006937 Hydatidiform mole Diseases 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000010217 densitometric analysis Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 108091092562 ribozyme Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 206010004272 Benign hydatidiform mole Diseases 0.000 description 5
- 101000616722 Homo sapiens E3 ubiquitin-protein ligase SIAH1 Proteins 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 101710158668 Placental protein Proteins 0.000 description 5
- 102000008217 Pregnancy Proteins Human genes 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000002424 anti-apoptotic effect Effects 0.000 description 5
- 230000009918 complex formation Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000002991 immunohistochemical analysis Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000010798 ubiquitination Methods 0.000 description 5
- 230000034512 ubiquitination Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 4
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000009677 vaginal delivery Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 102000051485 Bcl-2 family Human genes 0.000 description 3
- 108700038897 Bcl-2 family Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000707245 Homo sapiens E3 ubiquitin-protein ligase SIAH2 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000005711 Keratin-7 Human genes 0.000 description 3
- 108010070507 Keratin-7 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 208000019547 Placental disease Diseases 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004252 chorionic villi Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000000640 hydroxylating effect Effects 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000036963 noncompetitive effect Effects 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000008844 regulatory mechanism Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000001644 umbilical artery Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- ISTWWSBLMQHYIQ-UHFFFAOYSA-N 2-methyl-2-(oxaloamino)propanoic acid Chemical compound OC(=O)C(C)(C)NC(=O)C(O)=O ISTWWSBLMQHYIQ-UHFFFAOYSA-N 0.000 description 2
- 208000002333 Asphyxia Neonatorum Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 206010008267 Cervical incompetence Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101710116362 E3 ubiquitin-protein ligase sina Proteins 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000034702 Multiple pregnancies Diseases 0.000 description 2
- 206010028923 Neonatal asphyxia Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 208000009014 Uterine Cervical Incompetence Diseases 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000008649 adaptation response Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000010438 iron metabolism Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000002966 oligonucleotide array Methods 0.000 description 2
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 208000033300 perinatal asphyxia Diseases 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000012113 pregnancy disease Diseases 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000004063 proteosomal degradation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000000685 uterine artery Anatomy 0.000 description 2
- 238000000827 velocimetry Methods 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000009206 Abruptio Placentae Diseases 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 102000008056 Aryl Hydrocarbon Receptor Nuclear Translocator Human genes 0.000 description 1
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101150023628 Bok gene Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010069150 Discordant twin Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 208000036646 First trimester pregnancy Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000746072 Homo sapiens Cullin-2 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101001082574 Homo sapiens Hypoxia-inducible factor 1-alpha inhibitor Proteins 0.000 description 1
- 101000835877 Homo sapiens Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101000652166 Homo sapiens Mothers against decapentaplegic homolog 7 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 102100030481 Hypoxia-inducible factor 1-alpha inhibitor Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 108700006140 Myeloid Cell Leukemia Sequence 1 Proteins 0.000 description 1
- 102000046234 Myeloid Cell Leukemia Sequence 1 Human genes 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036365 Normal labour Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710201068 Prolyl 4-hydroxylase 1 Proteins 0.000 description 1
- 101710201062 Prolyl 4-hydroxylase 2 Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101000984527 Pseudomonas putida Benzene 1,2-dioxygenase system ferredoxin subunit Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 108700032504 Smad2 Proteins 0.000 description 1
- 206010041092 Small for dates baby Diseases 0.000 description 1
- 208000034713 Spontaneous Rupture Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 1
- 102000053200 Von Hippel-Lindau Tumor Suppressor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009602 intrauterine growth Effects 0.000 description 1
- 235000020796 iron status Nutrition 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000012318 pareses Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 201000008532 placental abruption Diseases 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000025934 tissue morphogenesis Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008347 uteroplacental blood flow Effects 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78145706P | 2006-03-10 | 2006-03-10 | |
| US60/781,457 | 2006-03-10 | ||
| US89983607P | 2007-02-06 | 2007-02-06 | |
| US60/899,836 | 2007-02-06 | ||
| PCT/CA2007/000394 WO2007104145A1 (en) | 2006-03-10 | 2007-03-09 | Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007224967A1 true AU2007224967A1 (en) | 2007-09-20 |
Family
ID=38508994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007224967A Abandoned AU2007224967A1 (en) | 2006-03-10 | 2007-03-09 | Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090246773A1 (https=) |
| EP (1) | EP2122018A4 (https=) |
| JP (2) | JP2009529659A (https=) |
| AU (1) | AU2007224967A1 (https=) |
| CA (1) | CA2643167A1 (https=) |
| WO (1) | WO2007104145A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0968430A1 (en) | 1997-03-07 | 2000-01-05 | Mount Sinai Hospital Corporation | Methods to diagnose a required regulation of trophoblast invasion |
| CA2619256A1 (en) * | 2004-09-24 | 2006-03-30 | Mount Sinai Hospital | Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover |
| JP6389122B2 (ja) * | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| JP6132731B2 (ja) * | 2013-09-27 | 2017-05-24 | 富士フイルム株式会社 | 光計測装置 |
| AU2021225836A1 (en) | 2020-02-28 | 2022-09-15 | Elutia Inc. | Placental tissue compositions and methods |
| WO2021207168A1 (en) * | 2020-04-06 | 2021-10-14 | The Trustees Of The University Of Pennsylvania | Methods for using extracellular micro vesicles with syncytiotrophoblast markers to diagnose preeclampsia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0968430A1 (en) * | 1997-03-07 | 2000-01-05 | Mount Sinai Hospital Corporation | Methods to diagnose a required regulation of trophoblast invasion |
| AU2005248410B2 (en) * | 2004-05-27 | 2010-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential expression of molecules associated with acute stroke |
| CA2619256A1 (en) * | 2004-09-24 | 2006-03-30 | Mount Sinai Hospital | Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover |
-
2007
- 2007-03-09 EP EP07710725A patent/EP2122018A4/en not_active Withdrawn
- 2007-03-09 AU AU2007224967A patent/AU2007224967A1/en not_active Abandoned
- 2007-03-09 WO PCT/CA2007/000394 patent/WO2007104145A1/en not_active Ceased
- 2007-03-09 JP JP2008557567A patent/JP2009529659A/ja not_active Withdrawn
- 2007-03-09 US US12/282,395 patent/US20090246773A1/en not_active Abandoned
- 2007-03-09 CA CA002643167A patent/CA2643167A1/en not_active Abandoned
-
2010
- 2010-03-08 JP JP2010051154A patent/JP2010185878A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009529659A (ja) | 2009-08-20 |
| EP2122018A4 (en) | 2010-04-07 |
| CA2643167A1 (en) | 2007-09-20 |
| WO2007104145A1 (en) | 2007-09-20 |
| US20090246773A1 (en) | 2009-10-01 |
| JP2010185878A (ja) | 2010-08-26 |
| EP2122018A2 (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9518992B2 (en) | Kits for the diagnosis of pre-eclampsia or eclampsia | |
| Margioula-Siarkou et al. | The role of endoglin and its soluble form in pathogenesis of preeclampsia | |
| Zu Schwabedissen et al. | Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation | |
| Hagmann et al. | The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia | |
| Nevo et al. | Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 | |
| JP5715589B2 (ja) | 妊娠合併症を診断および処置する方法 | |
| Dymara-Konopka et al. | Angiogenic imbalance as a contributor of preeclampsia | |
| JP2009538915A (ja) | 妊娠の合併症を診断および治療する方法 | |
| Siddiqui et al. | Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker | |
| Denison et al. | Prokineticin-1: a novel mediator of the inflammatory response in third-trimester human placenta | |
| Duan et al. | CCN3 signaling is differently regulated in placental diseases preeclampsia and abnormally invasive placenta | |
| US20090246773A1 (en) | Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover | |
| JP2018513961A (ja) | 妊娠高血圧腎症のための診断アッセイ及び治療 | |
| EP0968430A1 (en) | Methods to diagnose a required regulation of trophoblast invasion | |
| JP2009529659A5 (https=) | ||
| Massimiani et al. | Circulating EGFL7 distinguishes between IUGR and PE: an observational case–control study | |
| JP2008537776A (ja) | 妊娠期間中に胎児１３トリソミーまたは胎児１３トリソミーのリスクを診断する方法 | |
| CN109952511B (zh) | 用于确定先兆子痫的风险的测定方法 | |
| US20140038908A1 (en) | Polynucleotides and Polypeptides Associated with Trophoblast Cell Death, Differentiation, Invasion and/or Cell Fusion and Turnover | |
| US8889132B2 (en) | Antibodies against human HIF-1α | |
| Eastabrook et al. | Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK3 | Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination |